Preclinical Evaluation of Vemurafenib as Therapy for BRAF^V600E Mutated Sarcomas.

ABSTRACT: The BRAF^V600E mutation, which in melanoma is targetable with vemurafenib, is also found in sarcomas and we here evaluate the therapeutic potential in sarcoma cell lines.

Methods

Four sarcoma cell lines harboring the BRAFV600E mutation, representing liposarcomas (SA-4 and SW872), Ewing sarcoma (A673) and atypical synovial sarcoma (SW982), were treated with vemurafenib and the effects on cell growth, apoptosis, cell cycle progression and cell signaling were determined.

Results

Vemurafenib induced a strong cytostatic effect in SA-4 cells, mainly due to cell cycle arrest, whereas only moderate levels of apoptosis were observed. However, a high dose was required compared to BRAF^V600E mutated melanoma cells, and removal of vemurafenib demonstrated that the con

SUBMITTER: Gouravan S 

PROVIDER: S-EPMC5979358 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature